MannKind (MNKD) UP On Positive Results from Final Two Pivotal Phase 3 Clinical Studies
Tweet Send to a Friend
MannKind Corporation (Nasdaq: MNKD) is trading up today 12% after announcing that it has met the primary endpoints of its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
